KR960004345A - 2-(2- 아미노-1,6- 디하이드로-6- 옥소-퓨린-9-일)메톡시-1,3- 프로판 디올 유도체 - Google Patents
2-(2- 아미노-1,6- 디하이드로-6- 옥소-퓨린-9-일)메톡시-1,3- 프로판 디올 유도체 Download PDFInfo
- Publication number
- KR960004345A KR960004345A KR1019950022600A KR19950022600A KR960004345A KR 960004345 A KR960004345 A KR 960004345A KR 1019950022600 A KR1019950022600 A KR 1019950022600A KR 19950022600 A KR19950022600 A KR 19950022600A KR 960004345 A KR960004345 A KR 960004345A
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- compound
- hydroxy
- oxo
- dihydro
- Prior art date
Links
- DLJZAAJMDOFQRP-UHFFFAOYSA-N 2-amino-9-(1,3-dihydroxy-1-methoxypropan-2-yl)-3h-purin-6-one Chemical class N1=C(N)NC(=O)C2=C1N(C(CO)C(O)OC)C=N2 DLJZAAJMDOFQRP-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 13
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims abstract 3
- 150000002148 esters Chemical class 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 26
- -1 2-amino-1,6-dihydro-6-oxo-purin-9-yl Chemical group 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-M L-valinate Chemical compound CC(C)[C@H](N)C([O-])=O KZSNJWFQEVHDMF-BYPYZUCNSA-M 0.000 claims 1
- 159000000021 acetate salts Chemical group 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000012876 carrier material Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 229960002963 ganciclovir Drugs 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 239000011968 lewis acid catalyst Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000005905 mesyloxy group Chemical group 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 229940100613 topical solution Drugs 0.000 claims 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 claims 1
- IVIIAEVMQHEPAY-UHFFFAOYSA-N tridodecyl phosphite Chemical compound CCCCCCCCCCCCOP(OCCCCCCCCCCCC)OCCCCCCCCCCCC IVIIAEVMQHEPAY-UHFFFAOYSA-N 0.000 claims 1
- 229960004295 valine Drugs 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
개선된 흡수율을 가지는 항바이러스성 약제로서 유용한, 2-(2-아미노-1,6-디하이드로-6-옥소-퓨린-9-일)메톡시-1,3-프로판디올로부터 유도된 L-모노발린 에스테르 및 그의 약학적으로 허용가능한 염을 개시하고 있다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (23)
- (R)- 또는 (S)-부분입체 이성체 또는 두 부분입체 이성체의 혼합물 형태의 화합물 2-(2-아미노-1,6-디하이드로-6-옥소-퓨린-9-일)메톡시-3-하이드록시-1-프로판일-L-발리네이트 또는 그의 약학적으로 허용가능한 염.
- 제1항에 있어서, 동량의 (R)- 및 (S)-부분입체 이성체를 함유하는 상기 혼합물을 포함하는 화합물.
- 제1항에 있어서, 약학적으로 허용가능한 염이 염산염 또는 아세트산염인 화합물.
- 제1항에 있어서, 결정 형태인 화합물.
- 제1항에 있어서, (R)-2-(2-아미노-1,6-디하이드로-6-옥소-퓨린-9-일)메톡시-3-하이드록시-1-프로판일-L-발리네이트 및 그의 약학적으로 허용가능한 염인 화합물.
- 제1항에 있어서, (S)-2-(2-아미노-1,6-디하이드로-6-옥소-퓨린-9-일)메톡시-3-하이드록시-1-프로판일-L-발리네이트 및 그의 약학적으로 허용가능한 염인 화합물.
- 제5항 또는 제6항에 있어서, 상기 염이 염산염인 화합물.
- 제5항 또는 제6항에 있어서, 상기 염이 아세트산염인 화합물.
- 임의적으로는 약학적으로 허용가능한 부형체 또는 담체 물질과 함께, 제1항 내지 제8항 중 어느 한 항에 따른 화합물을 포함하는 약학 조성물.
- 제9항에 있어서, 정맥내 투여용 약학 조성물.
- 하기 일반식의 화합물 :상기 식에서, P1은 수소 또는 하이드록시-보호기이고, 또한 P2는 아미노-보호기이다.
- 화합물 2-(2-아미노-1,6-디하이드로-6-옥소-퓨린-9-일)메톡시-3-하이드록시-1-프로판일-L-발리네이트 및 그의 약학적으로 허용가능한 염 또는 부분입체 이성체를 제조하기 위한, 하기 과정을 포함하는 방법: (a) 하기 일반식을 가지는 화합물로부터 아미노- 및/또는 하이드록시-보호기를 제거하여 화합물2-(2-아미노-1,6-디하이드로-6-옥소-퓨린-9-일)메톡시-3-하이드록시-1-프로판일-L-발리네이트 및 그의 약학적으로 허용가능한 염을 얻는 과정:(상기 식에서, P1은 하이드록시-보호기 또는 수소이고, P2는 아미노-보호기이고, 또한 P3은 수소 또는 P2임); 또는 (b) 화합물 2-(2-아미노-1,6-디하이드로-6-옥소-퓨린-9-일)메톡시-3-하이드록시-1-프로판일-L-발리네이트 및 그의 약학적으로 허용가능한 염으로 전환시키는 과정; 또는 (c) 2-(2-아미노-1,6-디하이드로-6-옥소-퓨린-9-일)메톡시-1,3-프로판디올(간시클로비르) 또는 그의 염을 L-발린의 활성화된 유도체로 에스테르화시키는 과정; 또는 (d) 임의적으로 치환된, 임의적으로 퍼실레이트 형태의 하기 일반식의 구아닌을, 임의적으로 루이스산 촉매의 존재하에, 일반식(여기에서, Y1, Y2및 Z에 대한 정의는 하기 기재된 바와 같음)의 2-치환된 글리세롤과 축합시켜 화합물 2-(2-아미노-1,6-디하이드로-6-옥소-퓨린-9-일)메톡시-3-하이드록시-1-프로판일-L-발리네이트를 제공하는 과정:(상기 식에서, P3는 수소 또는 아미노-보호기이고, Y1및 Y2는 독립적으로 할로, 저급 아실옥시, 저급 알킬옥시, 또는 아릴(저급)알킬옥시기이고, 또한 Z는 저급 아실옥시, 메톡시, 이소프로필옥시, 벤질옥시, 할로, 메실옥시 또는 토실옥시로부터 선택된 이탈기임); 또는 (e) 비스 에스테르 2-(2-아미노-1,6-디하이드로-6-옥소-퓨린-9-일)메톡시-1,3-프로판디일 비스(L-발리네이트) 또는 그의 염을 부분가수분해시켜 모노 에스테르 2-(2-아미노-1,6-디하이드로-6-옥소-퓨린-9-일)메톡시-3-하이드록시-1-프로판일-L-발리네이트 또는 그의 약학적으로 허용가능한 염을 제공하는 과정; 또는 (f) 2-(2-아미노-1,6-디하이드로-6-옥소-퓨린-9-일)메톡시-3-하이드록시-1-프로판일-L-발리네이트를 그의 (R) 및 (S) 부분입체 이성체로 분할시키는 과정.
- 제12항에 있어서, 아미노- 및 하이드록시-보호기의 제거를 산성 조건하에 수행하는 방법.
- 제1항 내지 제8항 중 어느 한 항에 있어서, 제12항 또는 제13항에 따른 방법으로 제조한 화합물.
- 제1항 내지 제8항 중 어느 한 항에 있어서, 치료 활성이 있는 약제로서의 화합물.
- 제1항 내지 제8항 중 어느 한 항에 있어서, 바이러스성 질환 및 관련 질환의 치료에 치료 활성이 있는 약제로서의 화합물.
- 제1항 내지 제8항 중 어느 한 항에 따른 화합물을 제조하기 위한 제11항에 따른 화합물의 용도.
- 약학 조성물을 제조하기 위한 제1항 내지 제8항 중 어느 한 항에 따른 화합물의 용도.
- 바이러스성 질환 및 관련 질환 치료용 약학 조성물을 제조하기 위한 제1항 내지 제8항 중 어느 한 항에 따른 화합물의 용도.
- 바이러스성 질환 및 관련 질환을 앓거나 앓을 위험에 처한 동물에게 치료 허용량의 제1항에 따른 화합물을 투여하는 것을 포함하는, 상기 동물을 치료하는 방법.
- 제20항에 있어서, 상기 화합물을 경구 투여하는 방법.
- 제20항에 있어서, 상기 화합물을 국소 용액으로 투여하는 방법.
- 제20항에 있어서, 상기 화합물을 정맥내 이식물로서 투여하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28189394A | 1994-07-28 | 1994-07-28 | |
| US08/281893 | 1994-07-28 | ||
| US8/281,893 | 1994-07-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR960004345A true KR960004345A (ko) | 1996-02-23 |
| KR100358626B1 KR100358626B1 (ko) | 2003-01-14 |
Family
ID=23079211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950022600A KR100358626B1 (ko) | 1994-07-28 | 1995-07-27 | 2-(2-아미노-1,6-디하이드로-6-옥소-퓨린-9-일)메톡시-1,3-프로판디올유도체 |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP0694547B1 (ko) |
| JP (1) | JP3090305B2 (ko) |
| KR (1) | KR100358626B1 (ko) |
| CN (1) | CN1045089C (ko) |
| AT (1) | ATE179173T1 (ko) |
| AU (1) | AU697107B2 (ko) |
| BR (1) | BR9503468A (ko) |
| CA (1) | CA2154721C (ko) |
| CO (1) | CO4410181A1 (ko) |
| CY (2) | CY2180B1 (ko) |
| CZ (1) | CZ290511B6 (ko) |
| DE (3) | DE10299032I2 (ko) |
| DK (1) | DK0694547T3 (ko) |
| ES (1) | ES2083348T3 (ko) |
| FI (1) | FI112080B (ko) |
| GR (2) | GR960300021T1 (ko) |
| HK (1) | HK1012339A1 (ko) |
| HU (1) | HU216867B (ko) |
| IL (1) | IL114735A (ko) |
| LU (1) | LU91136I2 (ko) |
| MA (1) | MA23631A1 (ko) |
| MY (1) | MY114393A (ko) |
| NL (1) | NL300071I2 (ko) |
| NO (2) | NO312899B1 (ko) |
| NZ (1) | NZ272652A (ko) |
| PE (1) | PE32296A1 (ko) |
| PL (1) | PL180609B1 (ko) |
| RU (1) | RU2133749C1 (ko) |
| SA (1) | SA95160158B1 (ko) |
| TR (1) | TR199500895A2 (ko) |
| TW (1) | TW434242B (ko) |
| UY (1) | UY24006A1 (ko) |
| ZA (1) | ZA956228B (ko) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030015655A (ko) * | 2001-08-17 | 2003-02-25 | 한미약품공업 주식회사 | 항암제의 경구흡수율을 증가시키는 인단계 화합물의결정성 산부가염, 이의 제조방법 및 이를 함유하는 약학적조성물 |
| KR102312533B1 (ko) | 2021-02-24 | 2021-10-15 | 주식회사 이웅 | 자동 스패너 |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
| CN1064683C (zh) * | 1996-01-26 | 2001-04-18 | 弗·哈夫曼-拉罗切有限公司 | 制备嘌呤衍生物的方法 |
| US5756736A (en) * | 1996-01-26 | 1998-05-26 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| US5840890A (en) * | 1996-01-26 | 1998-11-24 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| AU1592897A (en) * | 1996-01-26 | 1997-08-20 | F. Hoffmann-La Roche Ag | Process for preparing purine derivatives |
| US5700936A (en) * | 1996-01-26 | 1997-12-23 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate |
| US6703394B2 (en) | 1996-02-16 | 2004-03-09 | Medivir Ab | Acyclic nucleoside derivatives |
| US5869493A (en) * | 1996-02-16 | 1999-02-09 | Medivir Ab | Acyclic nucleoside derivatives |
| US6184376B1 (en) | 1997-02-10 | 2001-02-06 | Mediver Ab | Synthesis of acyclic nucleoside derivatives |
| CA2277151C (en) * | 1997-02-10 | 2007-04-17 | Medivir Ab | Synthesis of acyclic nucleoside derivatives |
| TR200000398T2 (tr) * | 1997-08-15 | 2000-07-21 | Medivir Ab | Hepatit B virüsü (HBV) retroviral ters transkriptaz ve DNA polimeraz inhibe edicilerini içeren antiviraller gibi nükleozidlerin analogları. |
| AU1711599A (en) * | 1997-12-19 | 1999-07-12 | Bristol-Myers Squibb Company | Prodrugs of lobucavir and methods of use |
| WO1999051613A1 (en) * | 1998-04-03 | 1999-10-14 | Medivir Ab | Prodrugs of phosphorous-containing pharmaceuticals |
| WO2003091215A1 (en) * | 2002-04-23 | 2003-11-06 | Aventis Pharmaceuticals Inc. | 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo’ b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors |
| CA2502219C (en) | 2002-10-16 | 2012-05-29 | Takeda Pharmaceutical Company Limited | A process for producing an amorphous isomer of lansoprazole |
| MXPA05007016A (es) | 2003-01-14 | 2005-09-12 | Gilead Sciences Inc | Composiciones y metodos para terapia antiviral de combinacion. |
| EP1660499A1 (en) * | 2003-08-28 | 2006-05-31 | Ranbaxy Laboratories Limited | Amorphous valganciclovir hydrochloride |
| AU2005264864B2 (en) | 2004-06-16 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Multiple PPI dosage form |
| PL2626368T3 (pl) * | 2004-07-19 | 2017-06-30 | Biocon Limited | Koniugaty insulina-oligomer, ich formulacje i zastosowania |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| ZA200702234B (en) * | 2006-03-21 | 2008-07-30 | Cipla Ltd | Preparation of ester of purine derivatives |
| CA2702356C (en) | 2007-10-12 | 2014-02-11 | Takeda Pharmaceuticals North America, Inc. | Pharmaceutical formulation comprising a proton pump inhibitor for the treatment of gastrointestinal conditions independent of food intake |
| CN103562207B (zh) * | 2011-05-31 | 2016-08-17 | 法尔玛赞公司 | 用于制备缬更昔洛韦的2-氨基-9-((2-苯基-1，3-二噁烷-5-基氧基)甲基)-1h-嘌呤-6(9h)-酮化合物的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8202626A (nl) * | 1982-06-29 | 1984-01-16 | Stichting Rega V Z W | Derivaten van 9-(2-hydroxyethoxymethyl)guanine. |
| IE842642L (en) * | 1983-10-31 | 1985-04-30 | Harvard College | Purine Derivatives |
| DE3583858D1 (de) * | 1984-12-12 | 1991-09-26 | Syntex Inc | Derivate von alcoxymethylaether und alcoxymethylester. |
| AP160A (en) * | 1987-08-15 | 1991-11-18 | The Wellcome Foundation Ltd | Therapeutic acyclic nucleosides. |
| AU618436B2 (en) * | 1988-12-19 | 1991-12-19 | Wellcome Foundation Limited, The | Antiviral cytosine and guanine derivatives |
-
1995
- 1995-07-10 PE PE1995273436A patent/PE32296A1/es not_active IP Right Cessation
- 1995-07-19 DE DE2002199032 patent/DE10299032I2/de active Active
- 1995-07-19 DK DK95111319T patent/DK0694547T3/da active
- 1995-07-19 DE DE0694547T patent/DE694547T1/de active Pending
- 1995-07-19 DE DE69509173T patent/DE69509173T2/de not_active Expired - Lifetime
- 1995-07-19 AT AT95111319T patent/ATE179173T1/de active
- 1995-07-19 ES ES95111319T patent/ES2083348T3/es not_active Expired - Lifetime
- 1995-07-19 EP EP95111319A patent/EP0694547B1/en not_active Expired - Lifetime
- 1995-07-21 TR TR95/00895A patent/TR199500895A2/xx unknown
- 1995-07-26 ZA ZA956228A patent/ZA956228B/xx unknown
- 1995-07-26 AU AU27195/95A patent/AU697107B2/en not_active Expired
- 1995-07-26 HU HU9502238A patent/HU216867B/hu unknown
- 1995-07-26 MA MA23971A patent/MA23631A1/fr unknown
- 1995-07-26 CA CA002154721A patent/CA2154721C/en not_active Expired - Lifetime
- 1995-07-26 NZ NZ272652A patent/NZ272652A/en not_active IP Right Cessation
- 1995-07-26 IL IL114735A patent/IL114735A/en not_active IP Right Cessation
- 1995-07-27 MY MYPI95002156A patent/MY114393A/en unknown
- 1995-07-27 TW TW084107779A patent/TW434242B/zh not_active IP Right Cessation
- 1995-07-27 KR KR1019950022600A patent/KR100358626B1/ko not_active IP Right Cessation
- 1995-07-27 NO NO19952977A patent/NO312899B1/no not_active IP Right Cessation
- 1995-07-27 CN CN95109671A patent/CN1045089C/zh not_active Expired - Lifetime
- 1995-07-27 UY UY24006A patent/UY24006A1/es not_active IP Right Cessation
- 1995-07-27 CZ CZ19951939A patent/CZ290511B6/cs not_active IP Right Cessation
- 1995-07-27 FI FI953592A patent/FI112080B/fi active Protection Beyond IP Right Term
- 1995-07-27 PL PL95309812A patent/PL180609B1/pl unknown
- 1995-07-27 CO CO95033418A patent/CO4410181A1/es unknown
- 1995-07-27 JP JP07190953A patent/JP3090305B2/ja not_active Expired - Lifetime
- 1995-07-27 RU RU95113148A patent/RU2133749C1/ru active
- 1995-07-27 BR BR9503468A patent/BR9503468A/pt active Search and Examination
- 1995-08-14 SA SA95160158A patent/SA95160158B1/ar unknown
-
1996
- 1996-04-30 GR GR960300021T patent/GR960300021T1/el unknown
-
1998
- 1998-12-15 HK HK98113443A patent/HK1012339A1/xx not_active IP Right Cessation
-
1999
- 1999-07-02 GR GR990401760T patent/GR3030678T3/el unknown
-
2000
- 2000-08-10 CY CY0000039A patent/CY2180B1/xx unknown
-
2001
- 2001-11-23 NL NL300071C patent/NL300071I2/nl unknown
-
2003
- 2003-01-10 NO NO2003001C patent/NO2003001I2/no unknown
- 2003-05-21 LU LU91136C patent/LU91136I2/fr unknown
-
2004
- 2004-10-20 CY CY200400003C patent/CY2004003I1/el unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030015655A (ko) * | 2001-08-17 | 2003-02-25 | 한미약품공업 주식회사 | 항암제의 경구흡수율을 증가시키는 인단계 화합물의결정성 산부가염, 이의 제조방법 및 이를 함유하는 약학적조성물 |
| KR102312533B1 (ko) | 2021-02-24 | 2021-10-15 | 주식회사 이웅 | 자동 스패너 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960004345A (ko) | 2-(2- 아미노-1,6- 디하이드로-6- 옥소-퓨린-9-일)메톡시-1,3- 프로판 디올 유도체 | |
| CN1070849C (zh) | 酶抑制剂 | |
| CZ286621B6 (cs) | Tromethaminová sůl (+)-(S)-2-(3-benzoylfenyl)propionové kyseliny, způsob její výroby a farmaceutický prostředek s jejím obsahem | |
| KR850700136A (ko) | 신규 구아닌 유도체 | |
| CZ283721B6 (cs) | Purinové deriváty a jejich farmaceutické použití | |
| RU97115713A (ru) | Соединения, содержащие бензопиран и способ их применения | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| US9012509B2 (en) | Method of treating non-alcoholic steatohepatitis | |
| DE69922529T2 (de) | Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten | |
| DE69427551T2 (de) | Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe | |
| US4599355A (en) | Treatment of sleep disorders | |
| JPS62212322A (ja) | 医薬組成物および処置法 | |
| EP2139463B1 (en) | Anti-infective agents | |
| ATE2622T1 (de) | 2-niedrigalkyl-7-substituierte-2 oder 3-cephem-4- carbonsaeuren, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
| JP2951344B2 (ja) | 化学療法における毒性特性の改良 | |
| EP0030632B1 (de) | Benzothiazolderivate, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung | |
| US5013751A (en) | (+) Suprofen esters and amides as opthalmic anti-inflammatory agents | |
| US4150125A (en) | Triglyceride ester of phosphonoacetic acid having antiviral activity | |
| KR102352728B1 (ko) | 트리글리세라이드, 총 콜레스테롤, 및 저밀도 지단백질의 혈중농도를 감소시키는 방법 | |
| JPS61502468A (ja) | Ｎ−置換ブチルアミド誘導体 | |
| DE69612671T2 (de) | Butyrat-medikamentvorstufen der milchsäure | |
| JP2878844B2 (ja) | Ｎ▲ｇ▼−モノメチル−ｌ−アルギニン塩酸塩誘導体および敗血性ショックの治療におけるこれらの使用 | |
| DE365519T1 (de) | Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten. | |
| JPS61263916A (ja) | プロドラツグ型の医薬品組成物およびその製造方法 | |
| JP3169144B2 (ja) | シクロペンタン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20120927 Year of fee payment: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20130927 Year of fee payment: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20140929 Year of fee payment: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20150930 Year of fee payment: 14 |
|
| EXPY | Expiration of term |